January 20, 2026 – For the tenth 12 months in a row, the Facilities for Medicare & Medicaid Providers (CMS) named McKesson a Certified Medical Information Registry (QCDR) accepted to take part within the Advantage-based Incentive Fee System (MIPS).
McKesson’s Follow Insights, a CMS-approved QCDR, a efficiency analytics device powered by Ontada®McKesson’s real-world oncology information and insights enterprise – collects and reviews scientific information for physicians utilizing the IKnowMed® digital well being report. This designation permits practices and suppliers to effectively submit information for each MIPS and customized QCDR high quality measures on to CMS, eliminating the necessity for a separate registry supplier and decreasing administrative burden.
McKesson’s Follow Insights gives 9 oncology-specific QCDR measures to drive enhancements within the high quality and value of care. Seven of those measures had been developed in collaboration with physicians within the US Oncology Community, a company of community-based healthcare suppliers supported by McKesson:
- Screening and reaching decision or enchancment of most cancers care wants
- Superior care planning in sufferers with metastatic most cancers
- Affected person-reported ache enchancment
- Supportive care medicine use within the final 14 days of life
- Hepatitis B serology testing and prophylactic remedy previous to receiving anti-CD20-targeted medication
- Mutation testing for stage IV lung most cancers accomplished earlier than initiation of focused remedy
- Use of prophylactic GCSF for most cancers sufferers receiving low-risk chemotherapy
Two further measures had been developed by the American Society of Medical Oncology (ASCO) and have been accepted for a fourth 12 months:
- Antiemetic remedy for antineoplastic medication with low and minimal emetic danger – avoidance of overuse
- Acceptable antiemetic remedy for antineoplastic brokers with excessive and average emetic danger
As well as, CMS retained two Follow Insights QCDR measures for inclusion within the 2026 Advancing Most cancers Care MIPS Worth Pathways: Mutation Testing for Stage IV Lung Most cancers and Use of Prophylactic GCSF for Sufferers Receiving Low-Danger Chemotherapy. This recognition underscores the worth of McKesson’s high quality measures in enhancing most cancers care.
New for 2026 is a patient-reported consequence measure that tracks whether or not emergency screening and follow-up interventions result in a significant enchancment or decision inside six months. Misery contains bodily, emotional, social, sensible and religious issues – key elements that affect affected person well-being and remedy outcomes. By monitoring this measure by means of McKesson’s Follow Insights’ QCDR, practices can achieve perception into the effectiveness of psychosocial care, serving to to ship well timed interventions and improved affected person help.
Proceed studying